| Public issue of [*] equity shares of face value Rs. 10 each ("equity shares") of Arch Pharmalabs Limited ("company" or "issuer") for cash at a price of Rs. [*] per equity share (including a share premium of Rs. [*] per equity share) ("issue price") aggregating to Rs.[*] crores, consisting of a fresh issue of [*] equity shares by the company aggregating upto Rs.135.00 crores ("fresh issue") and an offer for sale of 6,172,607 equity shares by India Advantage Fund II, India Advantage Fund V, Rainbow Fund, Dynamic India Fund I, Leverage India Fund and Swiss Technology Venture Capital Fund Private Limited ("the selling shareholders") aggregating to Rs. [*] crores ("offer for sale"). The fresh issue and the offer for sale are together referred to as the "issue". The issue comprises of a net issue to the public of [*] equity shares ("net issue") and a reservation of upto 200,000 equity shares for subscription by eligible employees (as defined here-in) on a competitive basis ("employee reservation portion"). The issue and the net issue will constitute [*]% and [*]%, respectively, of the post-issue paid-up equity share capital of the company.
The face value of the equity shares is Rs. 10 each
|
